Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21
Joshua Ofman, CEO and Director of GRAIL, Inc. (NASDAQ:GRAL), sold a significant amount of company stock on September 21, 2026, totaling $6,006,378 worth of shares. The sales occurred under a Rule 10b5-1 trading plan he put in place on December 2, 2025. Following the sale, GRAIL’s stock price rose to $126.89, nearing its 52-week high.
Despite the company’s market cap of $5.67 billion and ongoing losses, InvestingPro analysis indicates that GRAIL appears overvalued. In the same transaction, Ofman also bought 26,452 shares through stock options, exercising them at $14 per share, for a total cost of $370,328. As of the sale date, he owns 362,271 GRAIL shares directly and holds 37,032 derivative securities.
GRAIL reported a revenue of $44.7 million in Q2, exceeding expectations, but reported a loss of $2.56 per share. The FDA has approved the Galleri test for early cancer detection, with a 10-0 vote for safety and a 6-4 vote for effectiveness. Analysts have mixed opinions on GRAIL's market performance, with Canaccord Genuity maintaining a Buy rating and Mizuho raising its price target.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
